



IFW 1642/\$

Packet No.: 066797-0126

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Watkins, Jeffry D., et al. Customer No.: 41552
Appl. No. : 09/995,529 Confirmation No.: 2007
Filed : November 26, 2001
Title : HUMANIZED COLLAGEN ANTIBODIES
AND RELATED METHODS
Grp./A.U. : 1642
Examiner: : Rawlings, Stephen L.

CERTIFICATE OF MAILING (37 CFR § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR § 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 12, 2004.


Carrie Casey

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.


Also attached: PTO-1449 – Information Disclosure Listing of 29 References
28 References

Please charge my Deposit Account No. 502624 in the amount of \$180.00. An additional copy of this transmittal sheet is submitted herewith.

The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 502624, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP


Deborah L. Cadena
Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:cec
Facsimile: 858.597.1585
Date: November 12, 2004



Document No.: 066797-0126

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Watkins, Jeffrey D., et al.

Customer No.: 41552

Appl. No. : 09/995,529

Confirmation No.: 2007

Filed : November 26, 2001


Title : HUMANIZED COLLAGEN
ANTIBODIES AND RELATED
METHODS

Grp./A.U. : 1642

Examiner: : RAWLINGS, Stephen L.

CERTIFICATE OF MAILING (37 CFR § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 12, 2004


Carrie Casey

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

11/17/2004 AWONDAF1 00000005 502624 09995529

01 FC:1806 180.00 DA

Serial No.: 09/995,529

In accordance with 37 CFR 1.17(p), please charge the fee of \$180.00 to Deposit Account No. 502624.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP



Deborah L. Cadena

Registration No. 44,048

4370 La Jolla Village Drive, Suite 700

San Diego, CA 92122

858.535.9001 DLC:cec

Facsimile: 858.597.1585

Date: November 12, 2004

SDO 20041-1.066797.0126

INFORMATION DISCLOSURE IN AN APPLICATION

 ATTY. DOCKET NO.
066797-0126

 SERIAL NO.
09/995,529

 APPLICANT
Watkins, Jeffry D., et al.

 FILING DATE
November 26, 2001

 GROUP
1642

(PTO-1449)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code2 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 5,320,970	06-14-1994	EYRE et al.	
	2.	US 5,541,295	07-30-1996	BARRACH et al.	
	3.	US 5,693,762	12-02-1997	QUEEN et al.	
	4.	US 5,763,272	06-09-1998	NASER et al.	
	5.	US 6,030,792	02-29-2000	OTTERNESS et al.	
	6.	US 6,132,976	10-17-2000	POOLE et al.	
	7.	US 2003/0113331 A1	06-19-2003	BROOKS et al.	
	8.	US Serial No. 10/011,250		WATKINS, et al.	(Copy Not Provided)

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Code3 -Number 4 -Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
	9.	EP 0 510 949 A2	10-28-1992	POULETTY, P.		Yes	No
	10.	EP 0 528 767 A1	02-24-1993	SANDOR LTD.			
	11.	EP 0 921 395 A2	12-11-1998	DOWNS et al.			
	12.	EP 0 992 586 A2	10-07-1999	GRUSKIN et al.			
	13.	WO 94/14070 A1	06-23-1994	POOLE et al.			
	14.	WO 95/04282 A1	02-09-1995	NASER et al.			
	15.	WO 97/44059 A2	11-27-1997	POOLE et al.			
	16.	WO 97/48418 A1	12-24-1997	APPELBAUM et al.			
	17.	WO 98/35235 A1	08-13-1998	HOLLANDER et al.			
	18.	WO 99/06840 A1	02-11-1999	KRANE et al.			
	19.	WO 00/23593 A2	04-27-2000	FISCHER et al.			
	20.	WO 01/57226 A1	09-09-2001	LAROSA et al.			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	21.	BELLON, "Quantification and Specific Detection of Collagenous Proteins Using an Enzyme-Linked Immunosorbent Assay and an Immunoblotting for Cyanogen Bromide Peptides," <u>Analytical Biochemistry</u> 150, 188-202 (1985).
	22.	BROOKS et al., "Antiintegrin $\alpha_v\beta_3$ blocks human breast cancer growth and angiogenesis in human skin," <u>J. Clin Invest.</u> , 96:1815-1822 (1995).
	23.	ECKER et al., "Rational screening of oligonucleotide combinatorial libraries for drug discovery," <u>Nucleic Acids Research</u> 21:1853-1856 (1993).
	24.	JELLINEK et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994).

EXAMINER

DATE CONSIDERED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)		ATTY. DOCKET NO. 066797-0126	SERIAL NO. 09/995,529
		APPLICANT Watkins, Jeffry D., et al.	
		FILING DATE November 26, 2001	GROUP 1642
	25.	PETITCLERC et al., "Integrin $\alpha_v\beta_3$ Promotes M21 Melanoma Growth in Human Skin by Regulating Tumor Cell Survival," <u>Cancer Research</u> 59, 2724-2730 (1999).	
	26.	TIMPL, "Antibodies to Collagens and Procollagens," <u>Methods in Enzymology</u> 82:472-498 (1982).	
	27.	TUERK and GOLD, "Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase," <u>Science</u> 249:505-510 (1990).	
	28.	Watkins et al., "Engineering IgM Antibodies for Therapeutic Applications," IBC Antibody Engineering Conference, San Diego, December 2-6, 2001, Presented December 3, 2001	
	29.	WICK et al., "Characterization of Antibodies to Basement Membrane (Type IV) Collagen in Immunohistological Studies," <u>Immunobiol</u> , 156:372-381 (1979).	
EXAMINER		DATE CONSIDERED	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.